Key result
Management of antiplatelet therapy in patients requiring non-cardiac surgery after coronary stenting requires balancing the risks of operative hemorrhage and stent thrombosis.
Why the study?
How should antiplatelet therapy be managed in patients requiring non-cardiac surgery within 12 months of coronary stenting?
How should antiplatelet therapy be managed in patients requiring non-cardiac surgery within 12 months of coronary stenting?
This review discusses the complex management of antiplatelet therapy in patients requiring non-cardiac surgery after coronary stenting to balance bleeding and thrombosis risks.
Individualized perioperative decisions remain necessary in post-stent patients; review leaves open randomized data to standardize antiplatelet timing.
Coronary artery stenting is increasingly used as a treatment for coronary artery disease. A period of antiplatelet therapy is mandatory following coronary stenting, in order to minimise the risk of stent thrombosis. About 5% of patients who undergo coronary stenting will require non-cardiac surgery within 12 months, and the management of antiplatelet therapy in this setting is complex, requiring a balance between the risks of both operative haemorrhage and stent thrombosis. The available evidence to guide decision-making in the management of antiplatelet therapy in this setting is reviewed.
No takes yet. Share an insight, caveat, or question.
Luckie et al. (2009) conducted a review in Coronary artery disease requiring non-cardiac surgery after coronary stenting. Antiplatelet therapy was evaluated. Management of antiplatelet therapy in patients requiring non-cardiac surgery after coronary stenting requires balancing the risks of operative hemorrhage and stent thrombosis.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: